Condition
Type 2 Diabetes Mellitus in Obese
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 24 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
24 shownLifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With SemaglutideNCT06497595 · 2025-05-11
RECRUITINGBeta-Cell - Liver Interactions in Situations of Modified Beta-Cell FunctionNCT06682481 · 2024-11-22
RECRUITINGPioglitazone on Heart Failure in Type-2 Diabetes Mellitus ParticipantsNCT05838287 · 2023-07-10
RECRUITINGBrain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)NCT05277558 · 2022-05-24
RECRUITINGImplementation of a Peer Leader-facilitated Dyadic InterventionNCT06643806 · 2025-03-20
COMPLETEDLCMD for Type 2 Diabetes Remission: Evaluation of Effectiveness and Exploration of Individual DifferencesNCT06442150 · 2024-06-01
NOT_YET_RECRUITINGEffect of Cryolipolysis on Insulin ResistanceNCT06223490 · 2023-11-01
UNKNOWNSemaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DMNCT06005012 · 2023-07-25
ACTIVE_NOT_RECRUITINGA Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 DiabetesNCT05890950 · 2023-03-13
COMPLETEDProbiotic Lysate (Postbiotic and Metabiotic) Supplementation for Type 2 Diabetes Patients (DELI_Diab Study)NCT05770076 · 2023-02-01
COMPLETEDType 2 Diabetes Mellitus With Obesity and Dyslipidemia Treated by Chinese Herbal MedicineNCT05072990 · 2021-10-27
COMPLETEDGlucagon-like Peptide-1 Agonism With Very Low Calorie DietsNCT05606471 · 2021-09-15
UNKNOWNThe Influence of Physical Activity on the Gut Microbiome of Pre-Diabetic AdultsNCT04931836 · 2021-07-29
COMPLETEDA Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62NCT05409027 · 2021-07-23
COMPLETEDEffect of Subcutaneous Semaglutide on Kidney Transplant CandidacyNCT04741074 · 2021-07-23
TERMINATEDREmote SUpport for Low-Carbohydrate Treatment of Type 2 DiabetesNCT04916314 · 2021-07-01
COMPLETEDHeart Rate Variability-Guided Exercise Training in Type 2 DiabetesNCT04910997 · 2021-06-01
WITHDRAWNPhentermine/Topiramate for Uric Acid StonesNCT04621929 · 2021-03-31
COMPLETEDL-Cell Activity in Small Intestine as Biliopancreatic Loop in Obese Patients With DM2 Submitted to RYGBPNCT05446415 · 2020-02-05
UNKNOWNThe Effect of Exenatide on Fasting Bile AcidsNCT04303819 · 2020-01-05
COMPLETEDEffect of a Plant Rich Diet on in People With Type 2 Diabetes and ObesityNCT02977039 · 2019-11-01
WITHDRAWNProspective Interventional Study on Reversibility of Type 2 Diabetes Mellitus With Hypocaloric DietNCT04363710 · 2017-05-31
COMPLETEDDietary Intake, Eating Behavior, Physical Activity Level and Their Relationships With Glycemic and Weight Control in Hong Kong Chinese Type 2 Diabetic PatientsNCT02937987 · 2016-04-01
COMPLETEDGlycemic Profile by CGMS in Diabetic Patients After Bariatric SurgeryNCT04332354 · 2016-03-30
COMPLETEDCommon interventions
PlaceboDRUG2Aerobic exercise trainingOTHER1Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells.OTHER1CHAI dyad studyBEHAVIORAL1Chinese herb medicineDRUG1Citrate Salts, Allopurinol, DietCOMBINATION_PRODUCT1Cortisone-d8DRUG1CryolipolysisPROCEDURE1Exenatide treatmentDRUG1K-757 and K-833DRUG1Low Calorie DietOTHER1Low Carbohydrate dietBEHAVIORAL1Low-Calorie DietCOMBINATION_PRODUCT1Low-Calorie Medicine DietCOMBINATION_PRODUCT1Matching placebo to K-757 and K-833DRUG1Measurement of biomarkerOTHER1NDPR dietOTHER1ObservationalOTHER1Phentermine / Topiramate Oral ProductDRUG1Physical Activity InterventionBEHAVIORAL1PioglitazoneDRUG1PlaceboDIETARY_SUPPLEMENT1Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solutionDRUG1Probiotic lysate (postbiotic and metabiotic)DIETARY_SUPPLEMENT1routine care. No interventionOTHER1
Leading sponsors
Beijing Chao Yang Hospital
1
Beth Israel Deaconess Medical Center
1
Bogomolets National Medical University
1
Cairo University
1
Chinese University of Hong Kong
1
Geisinger Clinic
1
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
1
Kallyope Inc.
1
Max Healthcare Insititute Limited
1
Philippe Klee, MD-PhD
1
Rutgers, The State University of New Jersey
1
Shanghai Municipal Hospital of Traditional Chinese Medicine
1
Sheba Medical Center
1
Sparrow Pharmaceuticals
1
The University of Texas Health Science Center at San Antonio
1
Trial status mix
COMPLETED12
RECRUITING4
UNKNOWN3
WITHDRAWN2
ACTIVE_NOT_RECRUITING1
NOT_YET_RECRUITING1
TERMINATED1
Phase mix
NA11
PHASE12
PHASE22
PHASE42
PHASE31
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.